#LCSM Chat Topic 6-May-2021: The Hows and Whys of Cancer Research Advocacy

Cancer patient advocates first appeared decades ago, in the breast cancer community.  Patient advocates are dedicated to supporting patients and their loved ones, improving lung cancer education and awareness, and generating funds for advocacy and research.  With the advent of targeted therapies and immunotherapies for many types of cancer, the past ten years have seen a growing group of patients, survivors, and caregivers who have lived with cancer long enough to become active, knowledgeable advocates for their cancer community. There is another type of cancer patient advocate called a “research advocate.” Research… Read More

#LCSM Chat Topic 1-Apr-2021: Tell Us What You Want — We’re Listening

#LCSM Chat began almost eight years ago.  Since then, lung cancer screening, diagnosis, care, and treatment options — as well as social media platforms — have changed dramatically.  The #LCSM Chat team decided it was time to make some changes of our own.   Our first change is a happy announcement:  please join us in welcoming medical oncologist Charu Aggarwal, MD, MPH (@CharuAggarwalMD) to the #LCSM Chat Moderator Team! Charu is the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at Penn Medicine.  Our second change is a survey of #LCSM Chat… Read More

#LCSM Chat Topic 4-Mar-2021: Liquid Bx—It pays to be vein

Cancer diagnosis for solid tumors has traditionally relied on biopsied tumor tissue. For patients already diagnosed with lung cancer, blood-based liquid biopsies are increasingly being used to look for bits of tumor proteins or DNA that can help identify suitable treatment options. The US FDA has even approved two liquid biopsies that can detect actionable mutations in lung cancer. However, there are several liquid biopsies technologies, and researchers are exploring whether those could be used to answer other questions in the cancer space, such as: Early detection: Is cancer present? If so,… Read More